James E. Dentzer
2007 - Amicus Therapeutics
In 2007, James E. Dentzer earned a total compensation of $640.4K as Chief Financial Officer at Amicus Therapeutics, a 31% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $93,324 |
|---|---|
| Option Awards | $172,917 |
| Salary | $282,692 |
| Stock Awards | $91,500 |
| Total | $640,433 |
Dentzer received $282.7K in salary, accounting for 44% of the total pay in 2007.
Dentzer also received $93.3K in non-equity incentive plan, $172.9K in option awards and $91.5K in stock awards.
Rankings
In 2007, James E. Dentzer's compensation ranked 5,339th out of 8,700 executives tracked by ExecPay. In other words, Dentzer earned more than 38.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,339 out of 8,700 | 39th |
Division Manufacturing | 1,988 out of 3,314 | 40th |
Major group Chemicals And Allied Products | 432 out of 746 | 42nd |
Industry group Drugs | 285 out of 546 | 48th |
Industry Pharmaceutical Preparations | 206 out of 364 | 43rd |
Source: SEC filing on April 24, 2009.
Dentzer's colleagues
We found four more compensation records of executives who worked with James E. Dentzer at Amicus Therapeutics in 2007.